Developer docs
API playgroundTry for free, no card

Search company profiles

STXBP1 Foundation

Full company profile

uuid002w7to

Namestring
STXBP1 Foundation
Legal namestring
STXBP1 Foundation
Company typeenum
Private
Founded yearint
2017
Descriptiontext

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization (EIN #82-1439459) founded in 2017 by a group of parents of children affected by STXBP1-Related Disorders, a rare neurodevelopmental condition and genetic epilepsy estimated to affect 1 in 30,000 births. The Foundation operates as the central coordinating entity for the STXBP1 community, maintaining a global patient census of 1,157+ individuals across 44+ countries and serving four primary constituencies: patient families, academic researchers, clinicians, and pharmaceutical/biotech developers. It works to accelerate research and clinical trial readiness by funding grants, organizing the annual Summit+ conference, hosting fundraising events such as the Million Dollar Bike Ride and the FLOURISH campaign, and convening collaborations across the rare pediatric epilepsy landscape with peer organizations including Syngap Research Fund, Rett Syndrome Research Trust, CACNA1A Foundation, Loulou Foundation (CDKL5), and KCNQ2 Cure Alliance.

The Foundation does not develop commercial technology products; its core "platform" is the STARR natural history study (170+ participants) plus integrated data relationships with Ciitizen, Simons Searchlight, and RARE-X for longitudinal patient data. It has secured a regulatory asset in ICD-10 code QA0.0141 (effective October 2025), hosted an FDA Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting, and supports an active therapeutic pipeline of 18+ treatments in development, including the Capsida Biotherapeutics CAP-002 gene therapy program. Scientific direction is provided by Scientific Director James R. Goss, PhD, under President and Co-Founder Charlene Son Rigby.

The Foundation's business model is purely donation- and grant-driven: it raises revenue through the FLOURISH campaign, the Million Dollar Bike Ride, Move To Cure 5K, September Awareness Month initiatives, and direct family fundraising, and reinvests proceeds into research grants (e.g., $100K Innovation Grants to UC Davis, UCSF, and Buffalo labs) and natural history study infrastructure. Clinical site partners include Children's Hospital of Philadelphia, Baylor College of Medicine, Weill Cornell Medicine, UCSF, UC Davis, Cincinnati Children's Hospital, Stanford Children's Health, and Children's Hospital Colorado.

Short descriptiontext

STXBP1 Foundation is a 501(c)(3) parent-led nonprofit founded in 2017 that accelerates research and clinical trial readiness for STXBP1-Related Disorders, a rare genetic epilepsy, serving 1,157+ patients, researchers, clinicians, and biotech developers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
patient advocacy nonprofit, rare disease research, genetic epilepsy support, natural history studies, research grant funding
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code1 code
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Health Services8000
Product category
Patient Advocacy Nonprofit
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Donations and Fundraising
TypeGrants Donations
Description

STXBP1 Foundation generates revenue through charitable donations from individuals, families, and supporters. They run fundraising campaigns including the FLOURISH campaign and annual events.

stxbp1disorders.org
2Patient Assistance Programs
TypeProfessional Services
Description

The foundation offers Patient Assistance Programs to defray travel-related expenses for families participating in clinical studies and trials.

stxbp1disorders.org
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Technology or R&D, Operations, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization that operates as the central hub for the STXBP1-Related Disorders community. It funds academic and biotech research through Innovation Grants and the Million Dollar Bike Ride program, runs the STARR natural history study and associated patient registries, and provides educational resources, family support, and clinical trial navigation for patients affected by this rare genetic epilepsy (1 in 30,000 births). The foundation also leads advocacy efforts such as securing the ICD-10 code QA0.0141 and convening an annual Summit+ conference for researchers, clinicians, and families.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 1,157+ patients registered in global census (Q3 2024)
+5 more records
Product overview1 text field

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization, not a technology product company. The organization does not offer commercial software products or services. Instead, it provides patient advocacy, raises awareness, funds STXBP1-related research, connects patients with natural history studies, and offers resources and support for families affected by STXBP1-Related Disorders. The foundation facilitates participation in research studies including the STARR natural history study, Simons Searchlight, Citizen Health, and RARE-X data collection programs.

Product and service6 records
1STARR Natural History Study
CategoryNatural History Study / Clinical Research Program
Description

A multi-site clinical natural history study for STXBP1-Related Disorders, designed to provide regulatory-grade longitudinal data for clinical trial readiness. Enrollment is open to STXBP1 patients and families through clinical sites including CHOP, Baylor College of Medicine/Texas Children's Hospital, Children's Hospital Colorado, Weill Cornell Medicine, Cincinnati Children's Hospital, and Stanford Children's Health.

2Patient Assistance Program
CategoryPatient Support Services
Description

Foundation-run program to defray travel-related expenses for families participating in STXBP1 clinical studies and trials, addressing the travel burden associated with access to specialty clinical sites.

3Innovation Grants Program
CategoryResearch Grants
Description

Research grant program funding academic investigators at institutions such as UC Davis, UCSF, and University of Buffalo to advance STXBP1 research, including CRISPR activation gene therapy, high-throughput zebrafish drug screening, AAV9-based gene therapy, and respiratory cilia research.

4Annual Summit+ Conference
CategoryConference / Community Event
Description

Annual conference (held at CHOP) that convenes STXBP1 researchers, clinicians, and families for research presentations, networking, and community building. Includes a dedicated Researcher Roundtable track for scientific collaboration.

5Global Patient Census
CategoryPatient Registry / Data Program
Description

Quarterly global patient census tracking STXBP1 patients across 44+ countries (1,157+ patients as of Q3 2024, with 44% Europe, 32% North America, 16% Asia Pacific, 8% Rest of World), including 140 adults aged 18+. Data is collected through the STXBP1 Global Connect liaison network.

6FLOURISH Fundraising Campaign
CategoryFundraising Campaign
Description

Transformational fundraising campaign led by the Finn Beaubien family, raising $1.3M+ for the STARR study and clinical trial readiness. Family-driven peer-to-peer fundraising initiative that supports STXBP1 research infrastructure.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership26 partners
1Syngap Research Fund (SRF)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Co-funded $275,000 grant to Dr. Orrin Devinsky at NYU for seizure classification study. One of six rare disease organizations collaborating on clinical trial readiness research.

stxbp1disorders.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Co-funder of Dr. Devinsky's seizure classification research. Collaborative effort across rare epilepsy organizations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Co-funder of Dr. Devinsky's seizure classification research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Co-funder of Dr. Devinsky's seizure classification research.

5KCNQ2 Cure Alliance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Co-funder of Dr. Devinsky's seizure classification research.

stxbp1disorders.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-17
Description

STARR natural history study clinical site, part of the expansion in Phase 2 of the study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-17
Description

STARR natural history study clinical site and research partner. Houses Dr. Mingshan Xue's lab conducting gene therapy research (CAP-002) with Capsida Biotherapeutics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-17
Description

STARR natural history study clinical site for clinical trial readiness research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-17
Description

Added as STARR clinic site in Phase 2 expansion, funded by the Glazer Family.

10Stanford Children's Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-17
Description

Added as STARR clinic site in Phase 2 expansion to reduce travel burden for families on the West Coast.

stxbp1disorders.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-13
Description

Collaboration on CAP-002 gene therapy for STXBP1 disorders. Capsida developed first-in-class IV-administered gene therapy achieving brain-wide neuronal expression. Received orphan drug designation. CAP-002 SYNRGY clinical trial underway.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-17
Description

Collaboration on the STARR natural history study for clinical trial readiness. CHOP serves as the lead site for STXBP1 clinical research, housing the ENDD (Center for Epilepsy and Neurodevelopmental Disorders) and hosting the STXBP1 Summit+ conference annually.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

Partnership to develop a digital natural history study using medical records. Ciitizen's platform enables patients to share health records with researchers, consolidating data from multiple hospitals. Study enrolled 150 participants globally.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

Natural history study partnership collecting neurodevelopmental, medical, and autism data. Simons provides patient-reported outcomes and bio-samples. Data integrated with Ciitizen for comprehensive patient records.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

Collaborative platform for global data sharing and analysis for rare disorders. RARE-X collects cross-symptom survey data including neurological, GI, motor, and vision information. Integrated with Citizen Health data platform.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2021-04-15
Description

Neuroscience drug discovery platform collaboration with STXBP1 Foundation and 14 other rare disease patient organizations.

17Jacqueline Burre Lab / Zachary Grinspan, Weill Cornell
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-20
Description

First clinical trial for STXBP1 - 4-phenylbutyrate (4PB) targeting the STXBP1 protein. Funded by ODC Million Dollar Bike Ride and Clara Inspired.

stxbp1disorders.org
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-31
Description

Million Dollar Bike Ride grants for STXBP1 research. Awarded $71,658 grants to Jimmy Holder (Baylor) and Christopher Makinson (Columbia) for STXBP1 studies.

19Kyle Fink Lab, UC Davis
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

$100,000 Innovation Grant for CRISPR activation gene therapy to restore STXBP1 expression. Dr. Fink is Associate Director of Gene Therapy Center, developing next-generation gene therapies for neurodevelopmental disorders.

stxbp1disorders.org
20Scott Baraban Lab, UCSF
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

$100,000 Innovation Grant for high-throughput drug screen in zebrafish. Dr. Baraban performs large-scale phenotypic drug screening using STXBP1 zebrafish model to discover FDA-approved drug candidates.

stxbp1disorders.org
21Soo-Kyung Lee Lab, University of Buffalo
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

$100,000 Innovation Grant for AAV9-based gene therapy development. Funded by donor for STXBP1 patients Mackenzie and Megan Mitchell.

stxbp1disorders.org
22Helen Willsey Lab, UCSF
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Innovation Grant for studying STXBP1's role in respiratory cilia and breathing complications. Research uses patient-derived nasal brush cultures and frog models to understand respiratory issues in STXBP1 patients.

stxbp1disorders.org
23STXBP1 Global Connect
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Global network of country liaisons and associations connecting STXBP1 families worldwide. Collaborates on quarterly census data collection.

stxbp1disorders.org
24European STXBP1 Consortium (ESCO)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

European natural history study harmonized with STARR study protocol. ESCO registry tracking 145+ European patients.

stxbp1disorders.org
Strategic tierMajorTypeGTM or Marketing Partner
Description

Transformational fundraising campaign led by the Finn Beaubien family raising $1.3M+ for STARR study and clinical trial readiness.

26ENDD Center, Penn Medicine
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Center for Epilepsy and Neurodevelopmental Disorders providing co-funding for STARR study and clinical trial infrastructure.

stxbp1disorders.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Disease-specific foundation for CACNA1A-related disorders, another rare neurodevelopmental condition. Co-funds joint rare epilepsy research grants and operates with similar parent-led 501(c)(3) structure.

TypeBroad incumbent
Description

Larger, established epilepsy research foundation that funds across all epilepsies rather than a single genetic subtype. Represents the broader incumbent that STXBP1 Foundation complements or competes with for research funding and donor dollars.

TypeDirect peer
Description

Disease-specific foundation for Rett syndrome, another rare genetic neurodevelopmental disorder with active gene therapy programs. Co-funder on the Devinsky seizure classification study; operates a similar research-funding and natural history model at larger scale.

TypeDirect peer
Description

Foundation dedicated to CDKL5 deficiency disorder, a rare genetic epilepsy with similar patient population size and ultra-rare drug development challenges. Direct collaborator on multi-foundation research initiatives.

5KCNQ2 Cure Alliance
TypeDirect peer
Description

Foundation focused on KCNQ2-related epilepsy, a rare genetic neonatal-onset epilepsy. Co-funded the Devinsky study and serves a comparable role in its disease community with similar natural history and gene therapy approaches.

TypeDirect peer
Description

Established foundation for Dravet syndrome, a well-known rare genetic epilepsy. Operates a more mature version of the STXBP1 Foundation model with FDA-approved therapies (e.g., Fintepla) validating the rare epilepsy drug development pathway.

TypeBroad incumbent
Description

University-based center that administers the Million Dollar Bike Ride program funding multiple rare disease foundations including STXBP1. Functions as both a funding conduit and research infrastructure partner.

TypeBroad incumbent
Description

Major philanthropic funder of autism and neurodevelopmental disorder research; operates Simons Searchlight, which partners with STXBP1 Foundation for natural history data collection. Represents a much larger institutional counterpart with overlapping research priorities.

9Tuberous Sclerosis Alliance
TypeDirect peer
Description

Mature rare genetic disorder foundation with FDA-approved therapies (mTOR inhibitors) and a sophisticated natural history/registry infrastructure. Represents a more developed endpoint of the same organizational trajectory.

10Syngap Research Fund (SRF)
TypeDirect peer
Description

Disease-specific 501(c)(3) focused on SYNGAP1, another rare genetic neurodevelopmental disorder with overlapping epilepsy phenotype. Direct collaborator on the $275K Devinsky grant and similar ultra-rare genetic epilepsy foundation model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STXBP1 Foundation

Patient Advocacy Nonprofitstxbp1disorders.org

STXBP1 Foundation is a 501(c)(3) parent-led nonprofit founded in 2017 that accelerates research and clinical trial readiness for STXBP1-Related Disorders, a rare genetic epilepsy, serving 1,157+ patients, researchers, clinicians, and biotech developers worldwide.

What STXBP1 Foundation does

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization (EIN #82-1439459) founded in 2017 by a group of parents of children affected by STXBP1-Related Disorders, a rare neurodevelopmental condition and genetic epilepsy estimated to affect 1 in 30,000 births. The Foundation operates as the central coordinating entity for the STXBP1 community, maintaining a global patient census of 1,157+ individuals across 44+ countries and serving four primary constituencies: patient families, academic researchers, clinicians, and pharmaceutical/biotech developers. It works to accelerate research and clinical trial readiness by funding grants, organizing the annual Summit+ conference, hosting fundraising events such as the Million Dollar Bike Ride and the FLOURISH campaign, and convening collaborations across the rare pediatric epilepsy landscape with peer organizations including Syngap Research Fund, Rett Syndrome Research Trust, CACNA1A Foundation, Loulou Foundation (CDKL5), and KCNQ2 Cure Alliance.

The Foundation does not develop commercial technology products; its core "platform" is the STARR natural history study (170+ participants) plus integrated data relationships with Ciitizen, Simons Searchlight, and RARE-X for longitudinal patient data. It has secured a regulatory asset in ICD-10 code QA0.0141 (effective October 2025), hosted an FDA Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting, and supports an active therapeutic pipeline of 18+ treatments in development, including the Capsida Biotherapeutics CAP-002 gene therapy program. Scientific direction is provided by Scientific Director James R. Goss, PhD, under President and Co-Founder Charlene Son Rigby.

The Foundation's business model is purely donation- and grant-driven: it raises revenue through the FLOURISH campaign, the Million Dollar Bike Ride, Move To Cure 5K, September Awareness Month initiatives, and direct family fundraising, and reinvests proceeds into research grants (e.g., $100K Innovation Grants to UC Davis, UCSF, and Buffalo labs) and natural history study infrastructure. Clinical site partners include Children's Hospital of Philadelphia, Baylor College of Medicine, Weill Cornell Medicine, UCSF, UC Davis, Cincinnati Children's Hospital, Stanford Children's Health, and Children's Hospital Colorado.

STXBP1 Foundation firmographics

Firmographics
Name
STXBP1 Foundation
Legal name
STXBP1 Foundation
Website
https://stxbp1disorders.org
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
STXBP1 Foundation is a 501(c)(3) parent-led nonprofit founded in 2017 that accelerates research and clinical trial readiness for STXBP1-Related Disorders, a rare genetic epilepsy, serving 1,157+ patients, researchers, clinicians, and biotech developers worldwide.
Ownership category
akta.pro rank

STXBP1 Foundation industry classification

Industry
Product category
Patient Advocacy Nonprofit
NAICS
Voluntary Health Organizations (813212)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Patient advocacy nonprofit
  • Rare disease research
  • Genetic epilepsy support
  • Natural history studies
  • Research grant funding

Where STXBP1 Foundation is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

STXBP1 Foundation business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

  1. Donations and Fundraising: STXBP1 Foundation generates revenue through charitable donations from individuals, families, and supporters. They run fundraising campaigns including the FLOURISH campaign and annual events.
  2. Patient Assistance Programs: The foundation offers Patient Assistance Programs to defray travel-related expenses for families participating in clinical studies and trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

STXBP1 Foundation product offering

Product offering

Core offering

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization that operates as the central hub for the STXBP1-Related Disorders community. It funds academic and biotech research through Innovation Grants and the Million Dollar Bike Ride program, runs the STARR natural history study and associated patient registries, and provides educational resources, family support, and clinical trial navigation for patients affected by this rare genetic epilepsy (1 in 30,000 births). The foundation also leads advocacy efforts such as securing the ICD-10 code QA0.0141 and convening an annual Summit+ conference for researchers, clinicians, and families.

Product overview

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization, not a technology product company. The organization does not offer commercial software products or services. Instead, it provides patient advocacy, raises awareness, funds STXBP1-related research, connects patients with natural history studies, and offers resources and support for families affected by STXBP1-Related Disorders. The foundation facilitates participation in research studies including the STARR natural history study, Simons Searchlight, Citizen Health, and RARE-X data collection programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • STARR Natural History Study A multi-site clinical natural history study for STXBP1-Related Disorders, designed to provide regulatory-grade longitudinal data for clinical trial readiness. Enrollment is open to STXBP1 patients and families through clinical sites including CHOP, Baylor College of Medicine/Texas Children's Hospital, Children's Hospital Colorado, Weill Cornell Medicine, Cincinnati Children's Hospital, and Stanford Children's Health.
  • Patient Assistance Program Foundation-run program to defray travel-related expenses for families participating in STXBP1 clinical studies and trials, addressing the travel burden associated with access to specialty clinical sites.
  • Innovation Grants Program Research grant program funding academic investigators at institutions such as UC Davis, UCSF, and University of Buffalo to advance STXBP1 research, including CRISPR activation gene therapy, high-throughput zebrafish drug screening, AAV9-based gene therapy, and respiratory cilia research.
  • Annual Summit+ Conference Annual conference (held at CHOP) that convenes STXBP1 researchers, clinicians, and families for research presentations, networking, and community building. Includes a dedicated Researcher Roundtable track for scientific collaboration.
  • Global Patient Census Quarterly global patient census tracking STXBP1 patients across 44+ countries (1,157+ patients as of Q3 2024, with 44% Europe, 32% North America, 16% Asia Pacific, 8% Rest of World), including 140 adults aged 18+. Data is collected through the STXBP1 Global Connect liaison network.
  • FLOURISH Fundraising Campaign Transformational fundraising campaign led by the Finn Beaubien family, raising $1.3M+ for the STARR study and clinical trial readiness. Family-driven peer-to-peer fundraising initiative that supports STXBP1 research infrastructure.

Quantifiable outcome

  • 1,157+ patients registered in global census (Q3 2024)
  • +5 more outcomes

Companies that use STXBP1 Foundation

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

STXBP1 Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

STXBP1 Foundation partnerships and signals

Strategic signal

Partnerships

26 partnerships are on record, tiered core and major.

  • Syngap Research Fund (SRF)coreStrategic or Co-development Partner · 17 September 2024Co-funded $275,000 grant to Dr. Orrin Devinsky at NYU for seizure classification study. One of six rare disease organizations collaborating on clinical trial readiness research.
  • Rett Syndrome Research TrustcoreStrategic or Co-development Partner · 17 September 2024Co-funder of Dr. Devinsky's seizure classification research. Collaborative effort across rare epilepsy organizations.
  • CACNA1A FoundationcoreStrategic or Co-development Partner · 17 September 2024Co-funder of Dr. Devinsky's seizure classification research.
  • Loulou Foundation (CDKL5)coreStrategic or Co-development Partner · 17 September 2024Co-funder of Dr. Devinsky's seizure classification research.
  • KCNQ2 Cure AlliancecoreStrategic or Co-development Partner · 17 September 2024Co-funder of Dr. Devinsky's seizure classification research.
  • Children's Hospital ColoradocoreStrategic or Co-development Partner · 17 July 2024STARR natural history study clinical site, part of the expansion in Phase 2 of the study.
  • Baylor College of Medicine / Texas Children's HospitalcoreStrategic or Co-development Partner · 17 July 2024STARR natural history study clinical site and research partner. Houses Dr. Mingshan Xue's lab conducting gene therapy research (CAP-002) with Capsida Biotherapeutics.
  • Weill Cornell MedicinecoreStrategic or Co-development Partner · 17 July 2024STARR natural history study clinical site for clinical trial readiness research.
  • Cincinnati Children's HospitalcoreStrategic or Co-development Partner · 17 July 2024Added as STARR clinic site in Phase 2 expansion, funded by the Glazer Family.
  • Stanford Children's HealthcoreStrategic or Co-development Partner · 17 July 2024Added as STARR clinic site in Phase 2 expansion to reduce travel burden for families on the West Coast.
  • Capsida BiotherapeuticscoreStrategic or Co-development Partner · 13 May 2024Collaboration on CAP-002 gene therapy for STXBP1 disorders. Capsida developed first-in-class IV-administered gene therapy achieving brain-wide neuronal expression. Received orphan drug designation. CAP-002 SYNRGY clinical trial underway.
  • Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 17 July 2023Collaboration on the STARR natural history study for clinical trial readiness. CHOP serves as the lead site for STXBP1 clinical research, housing the ENDD (Center for Epilepsy and Neurodevelopmental Disorders) and hosting the STXBP1 Summit+ conference annually.
  • Ciitizen (Citizen Health)coreStrategic or Co-development Partner · 15 April 2021Partnership to develop a digital natural history study using medical records. Ciitizen's platform enables patients to share health records with researchers, consolidating data from multiple hospitals. Study enrolled 150 participants globally.
  • Simons SearchlightcoreStrategic or Co-development Partner · 15 April 2021Natural history study partnership collecting neurodevelopmental, medical, and autism data. Simons provides patient-reported outcomes and bio-samples. Data integrated with Ciitizen for comprehensive patient records.
  • RARE-XcoreStrategic or Co-development Partner · 15 April 2021Collaborative platform for global data sharing and analysis for rare disorders. RARE-X collects cross-symptom survey data including neurological, GI, motor, and vision information. Integrated with Citizen Health data platform.
  • RarebasemajorTechnology or Integration · 15 April 2021Neuroscience drug discovery platform collaboration with STXBP1 Foundation and 14 other rare disease patient organizations.
  • Jacqueline Burre Lab / Zachary Grinspan, Weill CornellcoreStrategic or Co-development Partner · 20 February 2021First clinical trial for STXBP1 - 4-phenylbutyrate (4PB) targeting the STXBP1 protein. Funded by ODC Million Dollar Bike Ride and Clara Inspired.
  • Orphan Disease Center (University of Pennsylvania)majorStrategic or Co-development Partner · 31 January 2020Million Dollar Bike Ride grants for STXBP1 research. Awarded $71,658 grants to Jimmy Holder (Baylor) and Christopher Makinson (Columbia) for STXBP1 studies.
  • Kyle Fink Lab, UC DavismajorStrategic or Co-development Partner · 1 January 2020$100,000 Innovation Grant for CRISPR activation gene therapy to restore STXBP1 expression. Dr. Fink is Associate Director of Gene Therapy Center, developing next-generation gene therapies for neurodevelopmental disorders.
  • Scott Baraban Lab, UCSFmajorStrategic or Co-development Partner · 1 January 2020$100,000 Innovation Grant for high-throughput drug screen in zebrafish. Dr. Baraban performs large-scale phenotypic drug screening using STXBP1 zebrafish model to discover FDA-approved drug candidates.
  • Soo-Kyung Lee Lab, University of BuffalomajorStrategic or Co-development Partner · 1 January 2020$100,000 Innovation Grant for AAV9-based gene therapy development. Funded by donor for STXBP1 patients Mackenzie and Megan Mitchell.
  • Helen Willsey Lab, UCSFmajorStrategic or Co-development Partner · 1 January 2020Innovation Grant for studying STXBP1's role in respiratory cilia and breathing complications. Research uses patient-derived nasal brush cultures and frog models to understand respiratory issues in STXBP1 patients.
  • STXBP1 Global ConnectcoreStrategic or Co-development Partner · 1 January 2017Global network of country liaisons and associations connecting STXBP1 families worldwide. Collaborates on quarterly census data collection.
  • European STXBP1 Consortium (ESCO)coreStrategic or Co-development PartnerEuropean natural history study harmonized with STARR study protocol. ESCO registry tracking 145+ European patients.
  • FLOURISH Campaign (Finn Beaubien Family)majorGTM or Marketing PartnerTransformational fundraising campaign led by the Finn Beaubien family raising $1.3M+ for STARR study and clinical trial readiness.
  • ENDD Center, Penn MedicinecoreStrategic or Co-development PartnerCenter for Epilepsy and Neurodevelopmental Disorders providing co-funding for STARR study and clinical trial infrastructure.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

STXBP1 Foundation competitors and assessment

Company assessment

Direct peers

  • CACNA1A Foundation: Disease-specific foundation for CACNA1A-related disorders, another rare neurodevelopmental condition. Co-funds joint rare epilepsy research grants and operates with similar parent-led 501(c)(3) structure.
  • Rett Syndrome Research Trust: Disease-specific foundation for Rett syndrome, another rare genetic neurodevelopmental disorder with active gene therapy programs. Co-funder on the Devinsky seizure classification study; operates a similar research-funding and natural history model at larger scale.
  • Loulou Foundation (CDKL5 Deficiency Disorder): Foundation dedicated to CDKL5 deficiency disorder, a rare genetic epilepsy with similar patient population size and ultra-rare drug development challenges. Direct collaborator on multi-foundation research initiatives.
  • KCNQ2 Cure Alliance: Foundation focused on KCNQ2-related epilepsy, a rare genetic neonatal-onset epilepsy. Co-funded the Devinsky study and serves a comparable role in its disease community with similar natural history and gene therapy approaches.
  • Dravet Syndrome Foundation: Established foundation for Dravet syndrome, a well-known rare genetic epilepsy. Operates a more mature version of the STXBP1 Foundation model with FDA-approved therapies (e.g., Fintepla) validating the rare epilepsy drug development pathway.
  • Tuberous Sclerosis Alliance: Mature rare genetic disorder foundation with FDA-approved therapies (mTOR inhibitors) and a sophisticated natural history/registry infrastructure. Represents a more developed endpoint of the same organizational trajectory.
  • Syngap Research Fund (SRF): Disease-specific 501(c)(3) focused on SYNGAP1, another rare genetic neurodevelopmental disorder with overlapping epilepsy phenotype. Direct collaborator on the $275K Devinsky grant and similar ultra-rare genetic epilepsy foundation model.

Broad incumbents

  • CURE Epilepsy: Larger, established epilepsy research foundation that funds across all epilepsies rather than a single genetic subtype. Represents the broader incumbent that STXBP1 Foundation complements or competes with for research funding and donor dollars.
  • Orphan Disease Center (University of Pennsylvania): University-based center that administers the Million Dollar Bike Ride program funding multiple rare disease foundations including STXBP1. Functions as both a funding conduit and research infrastructure partner.
  • Simons Foundation / SFARI: Major philanthropic funder of autism and neurodevelopmental disorder research; operates Simons Searchlight, which partners with STXBP1 Foundation for natural history data collection. Represents a much larger institutional counterpart with overlapping research priorities.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

STXBP1 Foundation social profiles

Digital presence

STXBP1 Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STXBP1 Foundation leadership team

Management profile

Number of profiles

Profiles2 records

STXBP1 Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STXBP1 Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STXBP1 Foundation

What does STXBP1 Foundation do?

STXBP1 Foundation is a 501(c)(3) nonprofit patient advocacy organization that operates as the central hub for the STXBP1-Related Disorders community. It funds academic and biotech research through Innovation Grants and the Million Dollar Bike Ride program, runs the STARR natural history study and associated patient registries, and provides educational resources, family support, and clinical trial navigation for patients affected by this rare genetic epilepsy (1 in 30,000 births). The foundation also leads advocacy efforts such as securing the ICD-10 code QA0.0141 and convening an annual Summit+ conference for researchers, clinicians, and families.

Is STXBP1 Foundation a public or private company?

STXBP1 Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was STXBP1 Foundation founded?

STXBP1 Foundation was founded in 2017. It employs 1 to 10 people.

Where is STXBP1 Foundation based?

STXBP1 Foundation is headquartered in Philadelphia, United States, in the North America region.

How does STXBP1 Foundation make money?

Two revenue lines are on record. Donations and Fundraising is the primary driver. The others are patient Assistance Programs.

Who are STXBP1 Foundation's main competitors?

Direct peers on record are CACNA1A Foundation, Rett Syndrome Research Trust, Loulou Foundation (CDKL5 Deficiency Disorder), KCNQ2 Cure Alliance, Dravet Syndrome Foundation, Tuberous Sclerosis Alliance and Syngap Research Fund (SRF). Broad incumbents are CURE Epilepsy, Orphan Disease Center (University of Pennsylvania) and Simons Foundation / SFARI.

Does STXBP1 Foundation have an API?

No public API is recorded for STXBP1 Foundation.

What industry is STXBP1 Foundation in?

STXBP1 Foundation's product category is Patient Advocacy Nonprofit. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales